PolyPid Ltd. (NASDAQ:PYPD) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of PolyPid Ltd. (NASDAQ:PYPD - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $12.40.Several research analysts recently weighed in on the company. Weiss Ratings restated a "sell (e+)" rating on shares of PolyPid in a research note on Wednesday, October 8th. Citigroup restated a "market outperform" rating on shares of PolyPid in a research note on Monday, December 1st. Roth Capital cut their price objective on shares of PolyPid from $10.00 to $9.00 and set a "buy" rating on the stock in a report on Thursday, November 13th. Wall Street Zen raised shares of PolyPid from a "sell" rating to a "hold" rating in a research report on Sunday, November 16th. Finally, HC Wainwright reissued a "buy" rating and set a $13.00 target price on shares of PolyPid in a research report on Wednesday, August 13th.View Our Latest Report on PYPDHedge Funds Weigh In On PolyPidA number of institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets raised its holdings in PolyPid by 56.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company's stock valued at $32,000 after acquiring an additional 3,500 shares during the last quarter. Lumbard & Kellner LLC purchased a new stake in shares of PolyPid in the second quarter valued at approximately $135,000. Finally, AIGH Capital Management LLC increased its holdings in shares of PolyPid by 27.0% in the second quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company's stock valued at $4,215,000 after purchasing an additional 253,727 shares during the last quarter. Hedge funds and other institutional investors own 26.47% of the company's stock. PolyPid Stock Up 0.3%NASDAQ PYPD opened at $3.98 on Tuesday. PolyPid has a 52 week low of $2.30 and a 52 week high of $4.07. The company has a 50 day moving average price of $3.60 and a 200 day moving average price of $3.47. The firm has a market cap of $63.28 million, a PE ratio of -1.34 and a beta of 1.49. PolyPid (NASDAQ:PYPD - Get Free Report) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.17. On average, equities research analysts anticipate that PolyPid will post -1.79 earnings per share for the current fiscal year. PolyPid Company Profile (Get Free Report)PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.Further ReadingFive stocks we like better than PolyPidESG Stocks, What Investors Should KnowWhat Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer HealthThe 3 Best Fintech Stocks to Buy Now3 Stocks Most Likely to Split in 2026Airline Stocks - Top Airline Stocks to Buy NowChargePoint's Comeback Story: Why This EV Stock Is Charging Up AgainThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in PolyPid Right Now?Before you consider PolyPid, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PolyPid wasn't on the list.While PolyPid currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here